ACE-031 vs Mod-GRF (1-29).

ACE-031 (ramatercept) is not a peptide but a recombinant fusion protein that joins the extracellular domain of the human activin receptor type IIB (ActRIIB) to the Fc region of IgG1. Developed by Acceleron Pharma, it works as a ligand trap that soaks up myostatin and related TGF-beta-family proteins that normally restrain muscle growth. It was engineered as a candidate therapy for muscle-wasting conditions, most prominently Duchenne muscular dystrophy (DMD). Unlike most compounds grouped with muscle peptides, it genuinely reached human clinical trials before its development was stopped.

Mod GRF 1-29 (commonly sold as "CJC-1295 without DAC") is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH). It is the same tetra-substituted GHRH(1-29) peptide backbone used in CJC-1295, but it lacks the maleimido "Drug Affinity Complex" (DAC) linker that the long-acting form carries, so it behaves as a short-acting GHRH secretagogue. Its parent fragment, native GHRH(1-29) ("sermorelin"), retains essentially the full GH-releasing activity of the 44-residue hormone, and the four engineered substitutions are added to slow enzymatic breakdown.

ActRIIB is a receptor through which myostatin (GDF-8), activins, and several other TGF-beta-superfamily ligands signal to limit skeletal muscle mass. By presenting a soluble decoy receptor, ACE-031 binds these ligands in the circulation and prevents them from activating ActRIIB on muscle, releasing the brake on muscle growth. Because the trap captures multiple ligands beyond myostatin, including some that act on blood vessels, it produces effects outside muscle as well. This mechanism was established in animal models and then probed directly in humans.

Like endogenous GHRH, the peptide binds the GHRH receptor on anterior-pituitary somatotrophs, raising intracellular cAMP and triggering pulsatile synthesis and release of growth hormone, which in turn drives hepatic IGF-1 production. The four amino-acid substitutions relative to native GHRH(1-29), typically described as D-Ala at position 2, Gln8, Ala15, and Leu27, are intended to resist degradation, with the D-alanine substitution at position 2 specifically blocking cleavage by dipeptidyl peptidase-IV (DPP-IV), the main enzyme that rapidly inactivates GHRH. Because it has no albumin-binding DAC tether, it is cleared quickly and is described as producing brief, pulse-like GH stimulation rather than the sustained "GH bleed" seen with the DAC version. It is mechanistically a secretagogue: it prompts the pituitary's own GH, rather than supplying GH directly.

ACE-031 has genuine human data. Attie et al. reported a single ascending-dose study in healthy postmenopausal women in Muscle & Nerve (2013, PMID 23169607), observing increases in lean mass and biomarker changes consistent with myostatin inhibition. That was a phase 1 design: a small, single-administration, dose-escalating study in a narrowly selected healthy population, sponsored by the developer Acceleron Pharma, with imaging and biomarker endpoints rather than measures of function, and without the duration needed to detect anything that emerges over months. Campbell et al. published the randomized, placebo-controlled trial in ambulatory boys with DMD in Muscle & Nerve (2017, PMID 27462804), which showed trends toward preserved 6-minute-walk distance, higher lean mass and bone mineral density, and lower fat mass, but was stopped early. Because the trial was terminated before completing enrollment and follow-up, the walking-distance result remained a trend rather than a demonstrated benefit, the study lost the statistical power it had been designed with, and no confirmatory trial was ever run. Every efficacy statement about ACE-031 therefore rests on an interrupted study. This places ACE-031 well beyond the preclinical status of most muscle compounds, even though it never demonstrated confirmed clinical efficacy. The wider myostatin-pathway field has repeated the same pattern. Domagrozumab, an anti-myostatin antibody, failed its primary endpoint in Duchenne muscular dystrophy. Bimagrumab, an ActRII-blocking antibody, has produced consistent increases in lean mass without delivering the functional outcomes originally sought, and its cardiac safety has been examined separately in older adults (PMID 41873146). Increasing muscle mass has proven considerably easier than improving what patients can actually do. For ACE-031 specifically there is no chronic exposure data, no published long-term follow-up of the participants who were treated, no completed outcome trial, and no development activity after the early 2010s from which to draw further evidence.

The well-known human trials in this family, Teichman et al. (JCEM, 2006), Ionescu & Frohman (JCEM, 2006), and Sackmann-Sala et al. (Growth Horm IGF Res, 2009), all studied CJC-1295 WITH DAC, the long-acting albumin-binding version, not the no-DAC Mod GRF 1-29; Alba et al. (2006) used a GHRH-knockout mouse model. There is no robust, peer-reviewed human clinical trial of Mod GRF 1-29 (the no-DAC peptide) under that name establishing efficacy or safety, so claims about it are largely inferred from GHRH/sermorelin pharmacology and from the DAC-form data rather than directly tested. The unmodified parent peptide, sermorelin/GHRH(1-29), was an FDA-approved diagnostic and pediatric GH agent and is the best-characterized human reference point. Most published mentions of the no-DAC compound itself come from anti-doping analytical chemistry (e.g., Henninge et al., Drug Test Anal, 2010, identifying CJC-1295 in an illicit preparation), which characterize the molecule but not its clinical effects. Honest bottom line: the human-versus-preclinical gap is wide here, and the short-acting form is plausible by analogy but essentially unproven in controlled human studies.

The DMD program was halted in 2011 for safety reasons. Investigators observed dose-related, non-muscle vascular effects, specifically epistaxis (nosebleeds), gum bleeding, and telangiectasias (small dilated skin vessels), attributed to the trap's activity on additional TGF-beta-family ligands. The mechanistic explanation is that a soluble ActRIIB decoy does not bind myostatin alone: it also sequesters activins and bone morphogenetic proteins that help maintain vascular integrity, so the bleeding signal is a predictable consequence of the trap's breadth rather than an idiosyncratic reaction. These events appeared in children being treated for a serious progressive disease, the population most willing to accept risk for benefit, and they were still judged unacceptable. Acceleron and its partner Shire ended the collaboration and did not restart development. Short-term human exposure is documented, but the compound was discontinued precisely because of these off-target vascular signals, and long-term safety was never established. There is no chronic dosing data, no published long-term follow-up of the boys who were exposed, and no immunogenicity or reproductive toxicology in the public record. Later programs targeting the same pathway were deliberately engineered for narrower ligand selectivity in order to avoid this exact problem. Anything sold online under the ACE-031 name is an unapproved recombinant protein produced outside pharmaceutical manufacturing controls, where identity, glycosylation, aggregation state, and endotoxin content are all unverified, and aggregated Fc-fusion proteins carry their own immunogenicity risk. The monitoring a real trial would demand, including vascular and bleeding assessment, dermatologic examination, and anti-drug antibody testing, does not exist outside a clinical setting.

Documented safety data specific to Mod GRF 1-29 are minimal because controlled human trials of the no-DAC peptide are lacking; what is known is extrapolated from GHRH analogs broadly. In studies of related GHRH analogs and sermorelin, injection-site reactions (redness, swelling), flushing, and headache are the most commonly reported effects, and any sustained elevation of the GH/IGF-1 axis carries theoretical concerns including fluid retention, joint discomfort, insulin resistance/altered glucose handling, and uncertainty about long-term proliferative risk because IGF-1 is mitogenic. A major real-world hazard is that material sold under this name is research-grade and unregulated, so purity, identity, sterility, and contamination are not assured; anti-doping case reports document the compound appearing in mislabeled or "unknown" pharmaceutical preparations. Interactions with somatostatin tone, other secretagogues, and underlying endocrine or oncologic conditions are not well characterized, and long-term human safety is simply unknown.

ACE-031 was never approved by the FDA or any other regulator, and its clinical development was terminated in the early 2010s after the DMD trial was stopped for safety. It is not a marketed drug and is not legitimately available for human use. Any product sold online as ACE-031 is unapproved research-grade material.

Mod GRF 1-29 / CJC-1295 without DAC is not approved by the FDA or any major regulator for any indication and is an investigational/research-use-only compound; its unmodified parent, sermorelin, was previously FDA-approved but has been commercially discontinued. As a GHRH analog it falls under the World Anti-Doping Agency (WADA) Prohibited List class S2 (peptide hormones / growth factors and related substances) and is banned in sport at all times.